Efficacy and safety of formoterol in Japanese patients with COPD.

Efficacy and safety of formoterol in Japanese patients with COPD. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Efficacy and safety of formoterol in Japanese patients with COPD. Abstract Text:

Yoshiaki Minakata,Hideya Iijima,Tsuneyuki Takahashi,Motohiko Miura,Hiromasa Ogawa,Keiji Kimura,Takeharu Koga,Masaharu Kinoshita,Tohru Tsuda,Hisamichi Aizawa,Masakazu Ichinose,Yoshiaki Minakata,Hideya Iijima,Tsuneyuki Takahashi,Motohiko Miura,Hiromasa Ogawa,Keiji Kimura,Takeharu Koga,Masaharu Kinoshita,Tohru Tsuda,Hisamichi Aizawa,Masakazu Ichinose,

OBJECTIVE: This study evaluated the efficacy and safety of the formoterol Turbuhaler at dosages of 4.5, 9 and 18 microg bid compared with placebo in Japanese patients with COPD. METHODS: In this randomized, double-blind, placebo-controlled, multicenter study, 36 patients with a pre-bronchodilator FEV(1) value within 40 to 70% of the predicted value were randomized to receive formoterol at doses of 4.5, 9, and 18 microg bid, and placebo, for 1 week in a crossover fashion. RESULTS: The primary outcome variable, one hour post-dose FEV(1) on the last day of the one week treatment period, was significantly higher for all formoterol dosages compared with placebo (p<0.001 for all doses); adjusted g-means for formoterol 4.5, 9 and 18 microg bid, and placebo, were 1.510 L, 1.491 L, 1.520 L and 1.342 L, respectively. All three dosages of formoterol also provided significantly better improvements than placebo in the secondary variables FVC, inspiratory capacity (IC) and morning and evening PEF. Results for IC and PEF indicated a trend towards a larger improvement at higher dosages. CONCLUSION: Treatment with formoterol at dosages of 4.5, 9 and 18 microg bid showed significantly superior effects to placebo on FEV(1) in Japanese patients with COPD. The results for some of the secondary variables (IC and PEF) indicated a trend towards larger improvements at higher dosages. All dosages of formoterol were well tolerated in Japanese patients.

Efficacy and safety of formoterol in Japanese patients with COPD. Publishing Authors By Initials

Y Minakata,H Iijima,T Takahashi,M Miura,H Ogawa,K Kimura,T Koga,M Kinoshita,T Tsuda,H Aizawa,M Ichinose,Y Minakata,H Iijima,T Takahashi,M Miura,H Ogawa,K Kimura,T Koga,M Kinoshita,T Tsuda,H Aizawa,M Ichinose,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Efficacy and safety of formoterol in Japanese patients with COPD. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Internal medicine (Tokyo, Japan)

VOLUME: 47

Page Numbers: 217-23

Journal Abbreviation: Intern. Med.

ISSN: 1349-7235

DAY: 15

MONTH: 02

YEAR: 2008

Efficacy and safety of formoterol in Japanese patients with COPD. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9204241

Efficacy and safety of formoterol in Japanese patients with COPD. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Efficacy and safety of formoterol in Japanese patients with COPD. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Efficacy and safety of formoterol in Japanese patients with COPD.

AFFILIATION: The Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan. masakazu@wakayama-med.ac.jp

Country: Japan

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Intern Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Efficacy and safety of formoterol in Japanese patients with COPD Related Publications

• A long-term survivor after aggressive treatment for tracheal adenoid cystic carcinoma: a case report.
• Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice.
• Baroreflex control of muscle sympathetic nerve activity: Activated muscle metaboreflex in humans: 210: 1:05 PM-1:30 PM.
• Bundle-like assemblies of cadmium hydroxide nanostrands and anionic dyes.
• Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta(2)-agonists.
• Decreased expression of antioxidant enzymes and increased expression of chemokines in COPD lung.
• Developmentally regulated expression of matrix metalloproteinases during fetal rat colon morphogenesis.
• Effects of glycosylation on swimming ability and flagellar polymorphic transformation in Pseudomonas syringae pv. tabaci 6605.
• Efficacy and safety of formoterol in Japanese patients with COPD.
• Expression and release of the a and b subunits for human coagulation factor XIII in baby hamster kidney (BHK) cells.
• Flagellin glycans from two pathovars of Pseudomonas syringae contain rhamnose in D and L configurations in different ratios and modified 4-amino-4,6-dideoxyglucose.
• Foam films obtained with ionic liquid.
• High-resolution MR cisternography of the cerebellopontine angle: 2D versus 3D fast spin-echo sequences.
• IF YOU HAVE A CASE AGAINST YOU.
• Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal beta(2)-agonist.
• Increased expression of tyrosine hydroxylase and anomalous neurites in catecholaminergic neurons of ATF-2 null mice.
• Isolation of 8'-Phosphate Ester Derivatives of Amicoumacins: Structure-activity Relationship of Hydroxy Amino Acid Moiety.
• MR imaging of the enlarged endolymphatic duct and sac syndrome by use of a 3D fast asymmetric spin-echo sequence: volume and signal-intensity measurement of the endolymphatic duct and sac and area measurement of the cochlear modiolus.
• Modulation of defense signal transduction by flagellin-induced WRKY41 transcription factor in Arabidopsis thaliana.
• Molecular mechanism for pterin-mediated inactivation of tyrosine hydroxylase: formation of insoluble aggregates of tyrosine hydroxylase.
• Multiple novel transcripts for apolipoprotein(a)-related gene II generated by alternative splicing in tissue- and cell type-specific manners.
• Muscle metaboreflex-induced increases in cardiac sympathetic activity vasoconstrict the coronary vasculature.
• Nitrative stress in refractory asthma.
• ON THE ISOLATION AND IDENTIFICATION OF S-METHYLCYSTEINE FROM HUMAN URINE.
• Oxidative and nitrative stress in bronchial asthma.
• Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level.
• Prevalence of COPD in primary care clinics: correlation with non-respiratory diseases.
• Regulation of human protein Z gene expression by liver-enriched transcription factor HNF-4alpha and ubiquitous factor Sp1.
• Subcellular distribution of mitochondrial ribosomal RNA in the mouse oocyte and zygote.
• [Pulmonary metastatic carcinoma of the rectum growing extensively in the bronchial lumen--a case report]